Systemic Lupus Erythematosus Clinical Trials in New York, New York

11 studies are recruiting for systemic lupus erythematosus in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. HEALTH Home Urinalysis Testing

   Study participants enrolled in the SAMPLE Biorepository (s14-00487) who have provided permission to be contacted for future research will be enrolled and randomized (1:1) two-arm controlled) to either 1) perform weekly home-based proteinuria testing in addition to standard of care or 2) standard of…

   Stage

   Not phased

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Run by

   NYU Langone Health

   See if you can join NCT07823478 on ClinicalTrials.gov

2. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

3. An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

   A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Research Site, New York, New York

   Locations

   103 in total

   Run by

   AstraZeneca

   See if you can join NCT05835310 on ClinicalTrials.gov

4. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

   The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

   Stage

   Phase 3

   Ages

   16 and older

   Site

   Sl0044 50077, New York, New York

   Locations

   242 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT06617325 on ClinicalTrials.gov

5. RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Columbia University Irving Medical Center, New York, New York

   Locations

   23 in total

   Run by

   Cabaletta Bio

   See if you can join NCT06121297 on ClinicalTrials.gov

6. A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

   The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with activ…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Columbia University Medical Center, New York, New York

   Locations

   58 in total

   Run by

   Amgen

   See if you can join NCT06570798 on ClinicalTrials.gov

7. Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

   Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, …

   Stage

   Phase 3

   Ages

   55 and older

   Site

   VA NY Harbor Healthcare System, New York, New York

   Locations

   12 in total

   Run by

   NYU Langone Health

   See if you can join NCT05799378 on ClinicalTrials.gov

8. Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

   The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in pat…

   Stage

   Not phased

   Ages

   18 to 45

   Site

   NYU Langone Medical Center/Hospital for Joint Diseases, New York, New York

   Locations

   10 in total

   Run by

   Hospital for Special Surgery, New York

   See if you can join NCT00198068 on ClinicalTrials.gov

9. Alnuctamab for Refractory SLE (LATTE Study)

   This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07219563 on ClinicalTrials.gov

10. Safety of the Herpes Zoster Subunit Vaccine in Lupus

    This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The …

    Stage

    Phase 4

    Ages

    18 to 90

    Site

    NYU Langone Health, New York, New York

    Locations

    2 in total

    Run by

    NYU Langone Health

    See if you can join NCT05559671 on ClinicalTrials.gov

11. Safety and Efficacy of ONT01 in Lupus

    ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purpose of this study is to better determine whether ONT01 is safe and tolerated by people with lupus nephritis or SLE. The study also looks at …

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Hospital for Special Surgery, New York, New York

    Run by

    Hospital for Special Surgery, New York

    See if you can join NCT07107659 on ClinicalTrials.gov